Compass Therapeutics (CMPX) Cash & Current Investments (2018 - 2026)

Compass Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $194.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 71.98% year-over-year to $194.7 million; the TTM figure through Mar 2026 stood at $194.7 million (up 71.98% YoY), while the FY2025 annual figure was $209.5 million, up 64.56% from the prior year.
• Cash & Current Investments came in at $194.7 million for Q1 2026 at Compass Therapeutics, down from $209.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $219.9 million in Q3 2025 to a low of $101.5 million in Q2 2025.
• A 5-year average of $155.4 million and a median of $152.5 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 372.95% in 2022 and sank 35.7% in 2025, its largest moves.
• Compass Therapeutics' Cash & Current Investments stood at $186.6 million in 2022, then slipped by 18.28% to $152.5 million in 2023, then slipped by 16.51% to $127.3 million in 2024, then surged by 64.56% to $209.5 million in 2025, then retreated by 7.06% to $194.7 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $194.7 million, $209.5 million, and $219.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison